Replies to post #220654 on Biotech Values

[DewDiligence]

EMIS' PR is actually about the convertible debt that has an exercise price of $0.50. The NVO stuff at the top is just a smokescreen.

[ronpopeil]

EMIS Wake-Up call. Oral Semaglutide key of Eligen EMIS Technology are number of amino acids. Vantage reports 7.2.2019: "The drug uses a transcellular carrier technology Novo has licensed from Emisphere, but Novo’s chief science officer Mads Krogsgaard Thomsen told Vantage in December that Eligen works for peptides of up to about 50-80 amino acids." I.e. dulaglutide (Lilly), glepaglutide, elsiglutide (both Zealand Pharma), teduglutide (Takeda), exenatide LAR (Astra Zeneca) etc. etc. all in this range. "Oral Insulin likely developed by Soma devices but tech is still years away from the clinic." Furthermore there are as reported:"A number of logistical considerations, such as the cost of producing the Soma devices." EMIS Eligen for time being 'The Holy Grail'..